

Gennaro Daniele

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/172185/publications.pdf>

Version: 2024-02-01

45
papers

1,521
citations

430843

18
h-index

315719

38
g-index

45
all docs

45
docs citations

45
times ranked

3107
citing authors

#	ARTICLE	IF	CITATIONS
1	Oncologic Drugs Approval in Europe for Solid Tumors: Overview of the Last 6 Years. <i>Cancers</i> , 2022, 14, 889.	3.7	12
2	Oregovomab: an investigational agent for the treatment of advanced ovarian cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 103-110.	4.1	9
3	Role of Immune Checkpoint Inhibitors in Cervical Cancer: From Preclinical to Clinical Data. <i>Cancers</i> , 2021, 13, 2089.	3.7	20
4	Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 875-882.	2.5	19
5	Modern Challenges for Early-Phase Clinical Trial Design and Biomarker Discovery in Metastatic Non-Small-Cell Lung Cancer. <i>Journal of Molecular Pathology</i> , 2021, 2, 207-222.	1.2	0
6	Breast Cancer Drug Approvals Issued by EMA: A Review of Clinical Trials. <i>Cancers</i> , 2021, 13, 5198.	3.7	10
7	Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer. <i>JAMA Network Open</i> , 2020, 3, e1918939.	5.9	40
8	Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 445-453.	2.4	15
9	Integration of PARP-inhibitors in ovarian cancer therapy. <i>Exploration of Targeted Anti-tumor Therapy</i> , 2020, 1, 171-182.	0.8	3
10	Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBEO phase 3 randomised trial. <i>European Journal of Cancer</i> , 2019, 118, 178-186.	2.8	39
11	Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials. <i>Lung Cancer</i> , 2019, 133, 62-68.	2.0	5
12	Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 2585-2592.	1.6	42
13	A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients. <i>Lung Cancer</i> , 2017, 108, 15-21.	2.0	10
14	Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial. <i>Gynecologic Oncology</i> , 2017, 144, 256-259.	1.4	38
15	A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization) Tj ETQq1 126784314ngBT /Over		
16	Afatinib: An overview of its clinical development in non-small-cell lung cancer and other tumors. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 143-151.	4.4	27
17	Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials. <i>Journal of Clinical Oncology</i> , 2015, 33, 910-915.	1.6	361
18	Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , 2015, 16, 561-568.	10.7	141

#	ARTICLE	IF	CITATIONS
19	Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis. PLoS ONE, 2015, 10, e0133488.	2.5	110
20	Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid - short RadioTherapy - rectum) Tj ETQq0 0 0gBT /Overat 10 Tf	2.5	110
21	A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2014, 20, 6284-6294.	7.0	24
22	New biological treatments for gynecological tumors: focus on angiogenesis. Expert Opinion on Biological Therapy, 2014, 14, 337-346.	3.1	6
23	Treatment of small cell lung cancer. Critical Reviews in Oncology/Hematology, 2014, 91, 257-270.	4.4	57
24	Combining Anti-Epidermal Growth Factor Receptor (EGFR) and Anti-Angiogenic Strategies in Advanced NSCLC: We Should have Known Better. Current Pharmaceutical Design, 2014, 20, 3901-3913.	1.9	7
25	Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives. Expert Review of Anticancer Therapy, 2013, 13, 1207-1218.	2.4	13
26	Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: The CAPPA-2 study. Lung Cancer, 2013, 81, 77-83.	2.0	51
27	Pharmacokinetic evaluation of capecitabine in breast cancer. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 225-235.	3.3	9
28	Integrated Therapeutic Approaches in the Treatment of Locally Advanced Non-small Cell Lung Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 844-851.	1.7	3
29	Potentiality and Boundaries of Use of Sorafenib in Patients with Hepatocellular Carcinoma: Awaiting the Results of Ongoing Clinical Trials. Cancers, 2012, 4, 549-565.	3.7	1
30	Prognostic evaluation and choice of second-line treatment for patients with advanced non-small-cell lung cancer. Lung Cancer Management, 2012, 1, 55-62.	1.5	1
31	Prognostic impact of education level of patients with advanced non-small cell lung cancer enrolled in clinical trials. Lung Cancer, 2012, 76, 457-464.	2.0	32
32	Cetuximab in non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2012, 12, 163-175.	2.4	22
33	FGF Receptor Inhibitors: Role in Cancer Therapy. Current Oncology Reports, 2012, 14, 111-119.	4.0	51
34	A randomized phase III trial comparing sorafenib plus best supportive care (BSC) versus BSC alone in Child-Pugh B patients (pts) with advanced hepatocellular carcinoma (HCC): The BOOST study.. Journal of Clinical Oncology, 2012, 30, TPS4151-TPS4151.	1.6	3
35	Anticancer effect of bisphosphonates: new insights from clinical trials and preclinical evidence. Expert Review of Anticancer Therapy, 2011, 11, 299-307.	2.4	5
36	Pharmacokinetic evaluation of zoledronic acid. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 911-918.	3.3	13

#	ARTICLE	IF	CITATIONS
37	Addition of erlotinib to fluoropyrimidine-oxaliplatin-based chemotherapy with or without bevacizumab: Two sequential phase I trials. <i>Experimental and Therapeutic Medicine</i> , 2011, 2, 449-455.	1.8	3
38	Gefitinib in Non Small Cell Lung Cancer. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-14.	3.0	19
39	Time Spent for Activation of Non-Profit Studies in Oncology in Italy. <i>PLoS ONE</i> , 2010, 5, e11864.	2.5	3
40	Vinorelbine for non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 493-510.	2.4	16
41	New drugs in advanced non-small-cell lung cancer: searching for the correct clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 1503-1514.	4.1	10
42	The role of bevacizumab in breast cancer. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 26-29.	2.2	2
43	Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti-EGFR Epidermal Growth Factor Receptor Drugs in Human Cancer Cells. <i>Clinical Cancer Research</i> , 2008, 14, 5069-5080.	7.0	139
44	Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. <i>Drug Resistance Updates</i> , 2007, 10, 81-100.	14.4	74
45	Immunotherapy in gynecological cancers. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , .	0.8	1